177 E COLORADO BLVD, PASADENA, CA
Reports Fiscal 2026 Second Quarter Results
Arrowhead Pharmaceuticals Elects Seven Directors at Annual Meeting
Reports Fiscal 2026 First Quarter Results
Annual Report to Security Holders
Arrowhead Pharmaceuticals Issues $700 Million Convertible Senior Notes
Prices Upsized Offerings of Convertible Senior Notes, Common Stock and Pre-Funded Warrants
Investor Presentation
Reports 2025 Fiscal Year-End Results
Q2
Q1
FY 2024
Amended Annual Report
Q3
Registration Statement for Securities to be Offered to Employees
Prospectus filed pursuant to Rule 424(b)(5)
S-3ASR
Additional Proxy Materials
Definitive Proxy Statement
Amended Notice of Proposed Sale of Securities
Statement of Changes in Beneficial Ownership
Notice of Proposed Sale of Securities
Schedule 13G - Ownership Report
Prospectus filed pursuant to Rule 305(b)(2)
Free Writing Prospectus